BRILINTA® (ticagrelor) tablets can lower your chance of another heart attack or stroke. Learn more about saving on BRILINTA, talking to your doctor, and. Patient Information Leaflet. Package leaflet: Information for the user. Brilique 90 mg film-coated tablets ticagrelor. Read all of this leaflet carefully before you start . 27 May This leaflet is part III of a three-part “Product. Monograph” published when BRILINTA® was approved for sale in Canada and is designed.

Author: Yozshuktilar Akisho
Country: Argentina
Language: English (Spanish)
Genre: Sex
Published (Last): 17 April 2013
Pages: 434
PDF File Size: 7.83 Mb
ePub File Size: 19.30 Mb
ISBN: 634-1-88390-159-8
Downloads: 88430
Price: Free* [*Free Regsitration Required]
Uploader: Akilkree

People who are treated with a stent, and stop taking Packge too soon, have a higher risk of getting a blood clot in the stent, having a heart attack, or dying.

After any initial dose, use with aspirin mg per day. Drugs with a possible risk for QT prolongation and TdP that should inser used cautiously with anagrelide include vorinostat.

Moderate Coadministration of ticagrelor and erythromycin may result in increased exposure to ticagrelor which may increase the bleeding risk. Velpatasvir is a CYP3A4 substrate. Major The concomitant use of dabrafenib and ticagrelor may lead to decreased ticagrelor concentrations and loss of efficacy. The manufacturer of clopidogrel advises that caution be used when used in combination with NSAIDs as an increase brolinta occult GI blood loss occurred when clopidogrel was used concomitantly with naproxen Obinutuzumab: Hypersensitivity reactions including angioedema have been reported.

Rule out other causes. Moderate Coadministration of ticagrelor and isavuconazonium may result in increased exposure to ticagrelor which may increase the bleeding risk. Ticagrelor is contraindicated in patients with hypersensitivity e. Patients receiving dialysis have not been studied.


Ticagrelor is a P-glycoprotein P-gp substrate and grapefruit is a P-gp inhibitor. DHEA is converted to androgens and estrogens within the human body and thus may affect hemostasis via androgenic or estrogenic effects. Patients receiving warfarin that initiate concomitant icosapent ethyl therapy should have their INR monitored more closely and the dose of warfarin adjusted accordingly.

No change in the pharmacokinetic parameters of either drug were noted. Ticagrelor is a P-glycoprotein P-gp substrate and simeprevir is a mild P-gp brilints. Ticagrelor is a P-glycoprotein P-gp substrate and quinidine is a P-gp inhibitor.

Major Consider the use of a rbilinta anti-platelet agent for patients with acute coronary syndrome who require concomitant sufentanil. Plavix has been shown to reduce the rate of death from any cause and the rate of a combined endpoint of death, re infarction, or stroke. Tenofovir alafenamide is a substrate for P-gp. Padkage Potassium Guaiacolsulfonate; Pseudoephedrine: Major Avoid coadministration of ticagrelor with oral topotecan due to increased topotecan exposure; ticagrelor may be administered with intravenous topotecan.

Maintenance doses of aspirin above mg decreased ticagrelor effectiveness in a clinical trial.

If these drugs are administered together, monitor patients for adverse effects, such as headache, fatigue, nausea, and diarrhea. Concomitant use is likely to lead to increased concentrations of temsirolimus and ticagrelor. Ticagrelor is a P-glycoprotein P-gp substrate and erythromycin is a P-gp inhibitor.

Use combination with caution and monitor for evidence of bleeding. Ritonavir and paritaprevir are CYP3A4 substrates, and ombitasvir, paritaprevir, and ritonavir are all substrates of P-gp. Ticagrelor is a P-glycoprotein P-gp substrate and lapatinib is a P-gp inhibitor. AV block, bradycardia, sick sinus syndrome, syncope. Coadministration may increase vincristine concentrations; monitor patients for vincristine toxicity if these drugs are used together.


Moderate Prasterone is contraindicated for use in patients with active deep vein thrombosis, pulmonary embolism or history of these conditions.

– File or directory not found.

Glecaprevir and ticagrelor are both substrates and inhibitors of P-glycoprotein P-gp. Prasterone is also contraindicated in patients with active arterial thromboembolic disease brilintaa example, stroke and myocardial infarctionor a history of these conditions. Mechanism of Action Ticagrelor and its major metabolite reversibly interact with the platelet P2Y12 ADP-receptor to prevent signal transduction and platelet activation.

Moderate Cautious use of injectable collagenase by patients taking platelet inhibitors is advised. Consider the benefits of breast-feeding, the risk of potential infant drug exposure, and the risk of an untreated or inadequately treated condition.

Minor Coadministration of ticagrelor and dronedarone may result in increased exposure to ticagrelor which may increase the bleeding risk.

PDR Search

Coadministration in patients with renal impairment may result in increased exposure to rivaroxaban compared with patients with normal renal function and no inhibitor use since both pathways of elimination are affected. Minor Coadministration of ticagrelor and boceprevir may result in increased exposure to ticagrelor which may increase the bleeding risk. Moderate Because dipyridamole is a platelet inhibitor, there is a potential additive risk for bleeding if dipyridamole is given in combination with other agents that affect hemostasis such as ADP receptor antagonists including clopidogrel, prasugrel, ticagrelor, or ticlopidine.